In myotubes established from the pioglitazone treated subgroup, we found no significant differences in the metabolic pathways, nor in the expressional levels of SLC22A16, PLEK and TTBK2, as previously detected in vivo in PCOS patients [19] (Table 3). Here, PLEK is linked to polycystic ovary syndrome.